研究人员正在寻找治疗某些类型晚期胃肠道（GI）癌症的新方法。研究药物 raludotatug deruxtecan（亦称 MK-5909、R-DXd 或 DS-6000a）是一种称为抗体药物偶联物（ADC）的药物。ADC 会附著于癌细胞上的蛋白，并传递治疗以摧毁这些细胞。 本研究的主要目标是了解癌症是否对治疗产生反应（缩小或消失）。
适应症：Gastrointestinal Cancer
入组条件
纳入标准
- Has one of the following cancers:
- Unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC)
- Unresectable or metastatic adenocarcinoma of the biliary tract \[intra- or extrahepatic holangiocarcinoma (CCA) or gallbladder cancer (GBC)\]
- Unresectable or metastatic colorectal adenocarcinoma
- Unresectable or metastatic gastric adenocarcinoma
- Gastroesophageal junction adenocarcinoma (GEJAC)
- Esophageal adenocarcinoma (EAC)
- Has received prior therapy for the cancer
- Has a life expectancy of at least 3 months
- If human immunodeficiency virus (HIV) infected, must have well controlled HIV on antiretroviral therapy (ART)
排除标准
- Has a history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids or has current ILD/pneumonitis, and/or suspected ILD/pneumonitis
- Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
- Has uncontrolled or significant cardiovascular disease
- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Active autoimmune disease that has required systemic treatment in the past 2 years
- Has not adequately recovered from major surgery or has ongoing surgical complications
- HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。